Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO-B) Buildings (2009 - 2022)

Bio-Rad Laboratories (BIO-B) reported Buildings of $393.6 million for Q4 2022, up 2.03% year-over-year from $385.8 million in Q4 2021, and up 2.03% on a QoQ basis from $385.8 million in Q4 2021.

Bio-Rad Laboratories (BIO-B) has 14 years of Buildings data on file, last reported at $393.6 million in Q4 2022.

  • Quarterly Buildings rose 2.03% year-over-year to $393.6 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $393.6 million (up 2.03% YoY) and the FY2022 annual result came in at $393.6 million, up 2.03% from the prior year.
  • Buildings improved to $393.6 million in Q4 2022 per BIO-B's latest filing, from $385.8 million in the prior quarter.
  • Across five years, Buildings topped out at $393.6 million in Q4 2022 and bottomed at $331.6 million in Q4 2018.
  • The 5-year median for Buildings is $363.0 million (2020), against an average of $363.1 million.
  • The widest annual swing landed in 2020, when Buildings gained 6.28%; it then increased 2.03% in 2022.
  • Tracing BIO-B's Buildings over 5 years: stood at $331.6 million in 2018, then rose by 3.03% to $341.6 million in 2019, then grew by 6.28% to $363.0 million in 2020, then rose by 6.27% to $385.8 million in 2021, then gained by 2.03% to $393.6 million in 2022.
  • Per Business Quant, the three latest BIO-B Buildings figures stand at $393.6 million (Q4 2022), $385.8 million (Q4 2021), and $363.0 million (Q4 2020).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Bio-Rad Laboratories - - 309.40 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2022 393.62 Mn
Dec 31, 2021 385.80 Mn
Dec 31, 2020 363.05 Mn
Dec 31, 2019 341.60 Mn
Dec 31, 2018 331.56 Mn
Dec 31, 2017 315.98 Mn
Dec 31, 2016 300.83 Mn
Dec 31, 2015 276.07 Mn
Dec 31, 2014 282.79 Mn
Dec 31, 2013 284.30 Mn
Dec 31, 2012 268.22 Mn
Dec 31, 2011 249.62 Mn
Dec 31, 2010 232.96 Mn
Dec 31, 2009 204.61 Mn